You are here

Article Text

Article menu
Download PDFPDF
Young investigator awards
YI-5 Mortality and VT in ebstein’s anomaly of the tricuspid valve: A prospective cardiovascular magnetic resonance study
  1. Riikka Rydman1,2,
  2. Yumi Shiina1,3,
  3. Gerhard-Paul Diller1,4,5,
  4. Koichiro Niwa3,
  5. Wei Li1,
  6. Hideki Uemura1,
  7. Anselm Uebing1,
  8. Sabine Ernst1,4,
  9. Tom Wong1,
  10. Dudley J Pennell MD FRCP1,4,
  11. Michael A Gatzoulis1,4,
  12. Sonya V Babu-Narayan1
  1. 1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital London
  2. 2Section of Clinical Physiology, Department of Molecular Medicine and Surgery, at Karolinska Institutet, Stockholm, Sweden
  3. 3Cardiovascular Centre, St. Luke’s International Hospital, Tokyo, Japan
  4. 4National Heart and Lung Institute, Imperial College
  5. 5Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany

Abstract

Aims Patients with Ebstein’s anomaly of the tricuspid valve (EA) are at risk of tachyarrhythmia, congestive heart failure and sudden cardiac death. We sought to determine the value of cardiovascular magnetic resonance (CMR) for predicting these outcomes.

Methods and Results Seventy-nine consecutive adult patients (aged 37 ± 15 years) with unrepaired EA underwent CMR and were followed prospectively for a median 3.4 (range 0.4–10.9) years for clinical outcomes, namely major adverse cardiovascular events (MACE: sustained ventricular tachycardia/heart failure hospital admission/cardiac transplantation/death) and first-onset atrial tachyarrhythmia (AT).

Univariable CMR predictors of MACE (n = 6) were right ventricular (RV) or left ventricular (LV) ejection fraction (HR 2.06 [95% CI 1.168–3.623], p = 0.012/5% and HR 2.35 [95% CI 1.348–4.082], p = 0.003/5%, respectively), LV stroke volume index (HR 2.82 [95% CI 1.212–7.092], p = 0.028/10mL) and cardiac index (HR 1.71 [95% CI 1.002–1.366], p = 0.037); all remained significant when tested solely for mortality. Prior history of AT (HR 11.16 [95% CI 1.30–95.81], p = 0.028) and NYHA class >2 (HR 7.66 [95% CI 1.54–38.20], p = 0.013) were also predictive of MACE; AT preceded all but one MACE events suggesting its potential role as an early marker of adverse outcome (p = 0.011). Bi-ventricular impairment carried nearly 9 fold increased risk of adverse outcome (HR 8–69 [95% CI 1.57–48.10], p = 0.001).

Univariable predictors for first-onset AT (n = 17; 21.5%) included functional RA volume index (HR 1.03[95% CI 1.01–1.04], p = 0.005), RV ejection fraction (HR 1.55 [95% CI 1.103–2.160], p = 0.011/5%)], RV/LV end diastolic volume ratio (HR 1.55 [95% CI 1.14–2.10], p = 0.005) and apical tricuspid septal leaflet displacement indexed to total LV septal length (HR 1.03 [95% CI 1.00–1.07], p = 0.041); the latter two combined enhanced risk prediction (HR 6.12 [95% CI 1.67–22.56], p = 0.007).

Conclusion CMR derived indices carry prognostic information regarding MACE and first-onset AT amongst adults with unrepaired EA. CMR may be included in the periodic surveillance of these patients.

http://dx.doi.org/10.1136/heartjnl-2016-309377.53

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.